Company / Shareholders' Equity
United Therapeutics Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.1B
FY2025
5-year range
$4.0B / $7.1B
FY2021-FY2025
Trend
+10.1%
vs FY2024
Sector context
#16 of 213
Health Care
What the data says
Among 213 Health Care companies, United Therapeutics is in the top 8% for shareholders' equity. Shareholders' Equity has increased for 6 consecutive years, from $2.8B in FY2019 to $7.1B in FY2025.
Based on SEC 10-K filings.
$7.1B in FY2025 with a 5-year CAGR of +15.9%. Top quartile in the Health Care sector.
Improved from $6.0B to $7.1B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +15.9%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 213This company $7.1B Sector average $2.5B
▼
+178.4% above sector average
Key checks
Key Insights
- United Therapeutics's shareholders' equity has grown for 6 consecutive years.
- 5-year CAGR of +15.9%, indicating consistent growth.
- In FY2025, shareholders' equity increased 10.1% year-over-year.
- Ranks #16 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.1B | +10.1% |
| FY2024 | $6.4B | +7.7% |
| FY2023 | $6.0B | +24.8% |
| FY2022 | $4.8B | +21.2% |
| FY2021 | $4.0B | +16.6% |
| FY2020 | $3.4B | +22.1% |
| FY2019 | $2.8B | -0.3% |
| FY2018 | $2.8B | +75.5% |
| FY2017 | $1.6B | -14.2% |
| FY2016 | $1.9B | +16.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026